Mauna Kea Technologies SAS (MKT), is an endomicroscopy device manufacturer. The company develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. It provides a confocal laser endomicroscopy platform. MKT’s Cellvizio is an endomicroscopy platform that provides microscopic images of tissue instantaneously and in a minimally-invasive way. The company also offers vasculature and vasodynamics studies, longitudinal monitoring of disease progression and in vivo histology. It provides technical support and training. MKT’s products are used for treatment of digestive diseases chronic acid reflux, pancreatic cysts , gastric disease and diagnosing respiratory diseases and also used in laboratories for research on small animals. The company has presence in North America, Europe and Asia. MKT is headquartered in Paris, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Mauna Kea Technologies SAS
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Mauna Kea Technologies SAS Company Overview
Mauna Kea Technologies SAS Company Snapshot
Mauna Kea Technologies SAS Pipeline Products and Ongoing Clinical Trials Overview
Mauna Kea Technologies SAS – Pipeline Analysis Overview
Mauna Kea Technologies SAS - Key Facts
Mauna Kea Technologies SAS - Major Products and Services
Mauna Kea Technologies SAS Pipeline Products by Development Stage
Mauna Kea Technologies SAS Pipeline Products Overview
Cellvizio - COVID-19
Cellvizio - COVID-19 Product Overview
Cellvizio - Food Allergy
Cellvizio - Food Allergy Product Overview
NIR-nCLE System
NIR-nCLE System Product Overview
Mauna Kea Technologies SAS - Key Competitors
Mauna Kea Technologies SAS - Key Employees
Mauna Kea Technologies SAS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mauna Kea Technologies SAS, Recent Developments
Oct 19, 2023: Mauna Kea Technologies Reports 74% Increase in 9-Month 2023 Sales
Oct 17, 2023: Mauna Kea Technologies Announces the Publication of Positive Results of a Randomized Controlled Trial in the Field of Interstitial Lung Disease
Sep 19, 2023: Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone
Jul 03, 2023: Mauna Kea Technologies Announces the Installation of Cellvizio at University College Cork - APC Microbiome Ireland for Inflammatory Bowel Disease (IBD) Applications
Jan 19, 2023: Mauna Kea Technologies Announces Sales for the Fourth Quarter and Full Year 2022
Jan 12, 2023: Mauna Kea Technologies announces the publication of results of the first in human clinical study combining robotic-assisted bronchoscopy and needle-based confocal laser endomicroscopy for lung cancer
Nov 16, 2022: Mauna Kea Technologies Reports its Financial Results for the First Half of 2022
Oct 31, 2022: Mauna Kea Technologies announces success of clinical trial on prediction of remission in patients with inflammatory bowel disease (IBD) and its publication in gastroenterology
Jul 06, 2022: Mauna Kea Technologies announces publication of a meta-analysis demonstrating cellvizio’s significant role in detection of esophageal dysplasia and cancer
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Mauna Kea Technologies SAS Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Mauna Kea Technologies SAS Pipeline Products by Equipment Type
Table 3: Mauna Kea Technologies SAS Pipeline Products by Indication
Table 4: Mauna Kea Technologies SAS, Key Facts
Table 5: Mauna Kea Technologies SAS, Major Products and Services
Table 6: Mauna Kea Technologies SAS Number of Pipeline Products by Development Stage
Table 7: Mauna Kea Technologies SAS Pipeline Products Summary by Development Stage